Cancer gene therapy companies focus on harnessing genetic engineering to treat and potentially cure various cancers. These firms employ innovative approaches, such as CAR-T and CRISPR technologies, to develop targeted therapies that operate at the cellular level. The industry is rapidly evolving, driven by advancements in genetic research and the growing demand for personalized medicine. With an increase in regulatory support and clinical trials, the potential for breakthrough therapies is vast. As understanding of tumor biology improves, these companies are becoming valuable partners in oncology, aiming to offer hope to patients through transformative treatments.

This listing features 25 cancer gene therapy companies varying in size, from small startups to larger enterprises, and spans multiple countries. Headquartered primarily in the United States, it includes firms established from 2009 up to 2022. Notable specializations include CAR T-cell therapies, genomic profiling, and innovative immunotherapies. Despite their differences, these companies share a commitment to advancing cancer treatment through genetic and cellular therapies, placing them at the forefront of modern oncological research. Their combined expertise highlights the importance of innovation in battling some of the toughest cancers.

Read on to discover the top cancer gene therapy companies.

Top 25 Cancer Gene Therapy Companies

1. Kite Pharma

• Website: kitepharma.com
• Ownership type: Corporate
• Headquarters: Santa Monica, California, United States (USA)
• Employee distribution: United States (USA) 65%, Netherlands 28%, United Kingdom (UK) 2%, Other 5%
• Latest funding: $11.9B, August 2017
• Founded year: 2009
• Headcount: 1001-5000
• LinkedIn: kite-pharma-inc-

Kite Pharma, founded in 2009 and based in Santa Monica, California, is a biotechnology company that focuses on developing innovative cancer immunotherapy products, particularly CAR T-cell therapies. The company aims to harness the immune system's power to treat various blood cancers, providing effective treatment options for patients. Kite operates with a strong emphasis on research and development, ensuring that advanced therapies are accessible to healthcare providers and patients alike. Since its acquisition by Gilead Sciences in 2017, Kite has accelerated its pipeline, which includes notable therapies such as Yescarta and Tecartus. The company is actively involved in clinical trials and has established a network of treatment centers to facilitate patient access to its therapies. Kite's commitment to improving cancer care is evident in its ongoing efforts to expand its therapeutic offerings and enhance the efficacy of its treatments.

2. Foundation Medicine

• Website: foundationmedicine.com
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 95%, Germany 3%, Other 1%
• Latest funding: $2.4B, January 2015
• Founded year: 2010
• Headcount: 1001-5000
• LinkedIn: foundation-medicine

Foundation Medicine, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2010. The company focuses on genomic profiling specifically for cancer treatment. They offer a range of genomic tests, including FoundationOne CDx, FoundationOne Liquid CDx, and FoundationOne Heme, which provide actionable insights for healthcare providers, biopharmaceutical companies, and researchers. These tests help identify genomic alterations in cancer patients, facilitating personalized treatment plans and clinical trial enrollment. Foundation Medicine has established a significant presence in the industry, having delivered over one million reports and contributed to more than 800 peer-reviewed publications. Their extensive genomic database, FoundationCore®, is one of the largest in the world, aiding in the understanding of tumor biology and the development of new therapies. The company has also played a pivotal role in the approval of companion diagnostics, holding a substantial share of CDx approvals in the United States. This positions them as a key partner for biopharma companies in drug development and commercialization.

3. PsiOxus

• Website: psioxus.com
• Ownership type: Private Equity
• Headquarters: Abingdon, England, United Kingdom (UK)
• Latest funding: $31.8M, May 2015
• Founded year: 2010
• Headcount: 51-200
• LinkedIn: psioxus

PsiOxus, also known as Akamis Bio, is a biotechnology company based in Abingdon, England, founded in 2010. The company specializes in tumor gene therapy, developing its proprietary Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics. These therapies are designed to enhance the immune system's ability to recognize and attack solid tumors. PsiOxus has a clinical-stage pipeline, with its lead program, NG-350A, currently in Phase 1b trials. The company has treated over 200 patients across various studies, showcasing a consistent safety profile and promising preliminary clinical activity. PsiOxus has received funding amounting to $31.75 million, indicating investor confidence in their innovative approach to cancer treatment. Their focus on collaborations with leaders in immuno-oncology further underscores their commitment to advancing cancer therapies.

4. Kelonia Therapeutics

• Website: keloniatx.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $50.0M, April 2022
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: kelonia-therapeutics

Kelonia Therapeutics is a biotechnology company based in Boston, Massachusetts, founded in 2017. The firm is dedicated to advancing genetic medicine, with a particular emphasis on developing innovative therapies for cancer, specifically through in vivo CAR T therapies. Their proprietary iGPS® technology is designed to enhance gene delivery, allowing for more effective treatment options for diseases like multiple myeloma. Kelonia's approach aims to make genetic therapies more accessible to patients by overcoming existing challenges in gene delivery. In April 2022, the company secured $50 million in Series A funding, which reflects strong investor interest in their mission. Recently, Kelonia has entered into a research collaboration with Astellas Pharma to develop novel immuno-oncology therapeutics, further solidifying its position in the cancer treatment arena. The company is committed to transforming the landscape of genetic medicine and improving patient outcomes.

5. Juventas Cell Therapy Corp.

• Website: juventas.cn
• Ownership type: Private Equity
• Headquarters: Tianjin, Tianjin, China
• Employee distribution: China 100%
• Latest funding: Series C, $63.3M, July 2021
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: %e5%90%88%e6%ba%90%e7%94%9f%e7%89%a9%e7%a7%91%e6%8a%80-%e5%a4%a9%e6%b4%a5-%e6%9c%89%e9%99%90%e5%85%ac%e5%8f%b8

Juventas Cell Therapy Corp., founded in 2018 and based in Tianjin, China, is a biopharmaceutical company focused on advancing cell and gene therapy. The company has carved out a niche in developing CAR-T cell therapies, particularly for blood cancers and autoimmune diseases. Their flagship product, CNCT19, is notable for being the first CAR-T therapy approved in China for treating relapsed or refractory B-cell acute lymphoblastic leukemia. This product showcases their innovative approach and commitment to patient care. Juventas collaborates with top medical institutions to enhance the accessibility of their therapies. With a recent Series C funding round raising over 63 million USD, they are well-positioned to continue their research and development efforts, aiming to expand their pipeline of therapies targeting various cancers and autoimmune conditions.

6. Interius BioTherapeutics

• Website: interiusbio.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $51.4M, June 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: interius-biotherapeutics

Interius BioTherapeutics is a biotechnology firm based in Philadelphia, Pennsylvania, founded in 2019. The company specializes in developing innovative gene therapies, particularly focusing on in vivo cell-specific gene delivery technologies. Their primary aim is to create CAR T cells for the treatment of hematologic malignancies, which include various types of blood cancers. Interius operates in the biotechnology and healthcare sectors, catering to patients and healthcare providers seeking advanced treatment options. The company has made significant strides in its research and development efforts, recently announcing the commencement of a Phase 1 clinical trial for its lead product, INT2104, which is designed to treat B cell malignancies. Interius has also secured substantial funding, including a Series B round of over $51 million, which underscores the confidence investors have in their innovative approach to cancer treatment. Their work is based on inventions from the University of Pennsylvania, highlighting a strong academic foundation in their research.

7. MedTherapy Biotech

• Website: medtherapybiotech.com
• Ownership type: Private
• Headquarters: Quincy, Massachusetts, United States (USA)
• Employee distribution: India 76%, United States (USA) 24%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: medtherapy

MedTherapy Biotech is a biotechnology company based in Quincy, Massachusetts, founded in 2018 by experts from Harvard and former executives from Novartis. The company specializes in cancer cell and gene therapies, focusing on CAR-T cell therapies and viral vector manufacturing. MedTherapy provides a full spectrum of services, including clinical and commercial manufacturing, regulatory support, and analytical services. Their mission is to make cancer gene therapy more affordable and accessible to patients worldwide. With a significant portion of their workforce located in India, they operate global manufacturing facilities that adhere to stringent cGMP standards. This allows them to produce high-quality therapies efficiently and at a reduced cost, addressing the pressing challenges of time and expense in the manufacturing of cancer treatments.

8. Asgard Therapeutics

• Website: asgardthx.com
• Ownership type: Venture Capital
• Headquarters: Jönköping, Jonkoping, Sweden
• Employee distribution: Sweden 100%
• Latest funding: Series A, $32.6M, March 2024
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: asgardthx

Asgard Therapeutics is a biotechnology firm based in Jönköping, Sweden, founded in 2018. The company specializes in cancer immunotherapy, focusing on the development of innovative gene therapies. Their flagship program, AT-108, is designed to reprogram tumor cells into professional antigen-presenting cells, enhancing the immune system's ability to recognize and attack cancer. Asgard Therapeutics operates within the biotechnology sector, emphasizing research and development to create advanced treatment options for cancer patients. The company has garnered attention for its promising approach and has successfully raised €30 million in Series A funding to support its clinical development. Their work has been recognized in scientific publications, showcasing their commitment to advancing cancer treatment through gene therapy.

9. Miltenyi Biomedicine

• Website: miltenyibiomedicine.com
• Ownership type: Private
• Headquarters: Bergisch Gladbach, North Rhine-Westphalia, Germany
• Employee distribution: Germany 81%, United States (USA) 13%, Other 6%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: miltenyi-biomedicine

Miltenyi Biomedicine, founded in 2019 and based in Bergisch Gladbach, Germany, is a biopharmaceutical company dedicated to the development of innovative cell and gene therapies aimed at treating serious diseases. The company is particularly focused on personalized treatments for cancer, with a strong emphasis on hematological cancers. Utilizing CAR T technology, Miltenyi Biomedicine is working on therapies that target difficult-to-treat cancers, such as diffuse large B cell lymphoma. Their operations include extensive research, development, and manufacturing of therapeutic products, ensuring that they are well-equipped to meet the needs of healthcare providers and patients. The company is committed to improving patient outcomes and quality of life through advanced medical solutions, and they are actively involved in clinical trials to bring their therapies to market.

10. BioSyngen

• Website: biosyngen.com
• Ownership type: Venture Capital
• Headquarters: Singapore, Singapore
• Employee distribution: Singapore 87%, China 13%
• Latest funding: $78.2M, October 2021
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: biosyngen

BioSyngen, founded in 2016 and based in Singapore, is a biotechnology firm dedicated to the development of cutting-edge cell and gene therapies for cancer treatment. The company aims to tackle significant unmet needs in oncology, particularly through innovative immunotherapies that target solid tumors. BioSyngen's operations span research and development, manufacturing, and collaboration with healthcare providers to enhance patient outcomes. They have a robust pipeline featuring three proven technologies in cancer gene therapy: CAR-T, TCR-T, and TIL, which are currently in various stages of clinical trials. The company has also secured substantial funding, with a reported amount of approximately $78 million in their last funding round in October 2021. This financial backing supports their ambitious goals in advancing cancer treatment options.

11. AvenCell

• Website: avencell.com
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: Germany 56%, United States (USA) 41%, France 3%
• Latest funding: Series B, $112.0M, October 2024
• Founded year: 2021
• Headcount: 51-200
• LinkedIn: avencell

AvenCell Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2021. The company specializes in developing innovative immunotherapies aimed at hard-to-treat cancers, with a particular emphasis on advanced CAR-T cell therapies. AvenCell's mission is to overcome the limitations of existing CAR-T therapies by enhancing their therapeutic windows and expanding the range of treatable cancers, including solid tumors. The company has a strong scientific foundation, leveraging proprietary technologies such as the Universal Switchable CAR and an allogeneic platform. AvenCell has received significant backing, with $112 million raised in a Series B funding round in October 2024, reflecting investor confidence in their approach and potential impact in the oncology space.

12. ImmunoACT

• Website: immunoact.com
• Ownership type: Private
• Headquarters: Navi Mumbai, Maharashtra, India
• Employee distribution: India 100%
• Latest funding: $484,000, May 2023
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: immunoact

ImmunoACT is a biotechnology firm based in Navi Mumbai, Maharashtra, India, founded in 2018. The company is dedicated to advancing cell and gene therapies, with a particular emphasis on CAR-T cell therapies. As India's first gene-modified cell therapy company, ImmunoACT operates from research and development through to manufacturing and commercialization. Their flagship product, NexCAR19, represents a significant innovation in cancer treatment, specifically targeting B-cell cancers such as Acute Lymphoblastic Leukaemia and Large B-cell Lymphomas. The company aims to provide affordable and accessible therapies to improve survival outcomes for patients facing significant medical challenges. ImmunoACT has also secured funding, with a reported amount of approximately $484,000 in May 2023, which supports their ongoing research and development efforts in the field of cancer therapy.

13. Imunopharm Technology

• Website: imunopharm.com
• Ownership type: Private
• Headquarters: Beijing, Beijing, China
• Employee distribution: China 100%
• Founded year: 2015
• Headcount: 201-500
• LinkedIn: immunochina

Beijing Imunopharm Technology Co., Ltd. is a biotechnology firm founded in 2015, based in Beijing, China. The company is dedicated to the development of innovative gene and cell therapies aimed at treating cancer. Imunopharm focuses on creating CAR-T products that target specific types of malignancies, catering to healthcare providers and organizations seeking advanced cancer treatment options. Their operations span research, development, and manufacturing of biological products, with a strong emphasis on clinical trials. Notably, Imunopharm has been recognized for its innovative technology platform and has made significant strides in the CAR-T therapy space, including recent advancements in treatments for metastatic colorectal cancer and liver cancer. The company has also been acknowledged in various industry rankings, reflecting its growing influence in the biotechnology sector.

14. A2 Biotherapeutics, Inc.

• Website: a2bio.com
• Ownership type: Venture Capital
• Headquarters: Agoura Hills, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $80.0M, January 2025
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: a2-biotherapeutics

A2 Biotherapeutics, Inc., founded in 2018 and based in Agoura Hills, California, is a biotechnology firm dedicated to advancing T cell therapies for solid tumors. The company has developed the Tmod™ platform, which enables the precise targeting of cancer cells while sparing healthy tissues. This innovative approach addresses a critical challenge in cancer treatment, as traditional therapies often harm normal cells alongside cancerous ones. A2 Biotherapeutics is actively involved in clinical trials, including the EVEREST-1 and EVEREST-2 trials, which focus on therapies targeting carcinoembryonic antigen (CEA) and mesothelin (MSLN) respectively. The company has successfully raised significant funding, including an $80 million Series C round in January 2025, which underscores investor confidence in their technology and pipeline. A2 Biotherapeutics is positioned to make a meaningful impact in the oncology space, particularly through their modular and flexible T cell therapy platform.

15. EXUMA Biotech

• Website: exumabio.com
• Ownership type: Corporate
• Headquarters: West Palm Beach, Florida, United States (USA)
• Latest funding: Series B, $41.0M, December 2021
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: f1-oncology

EXUMA Biotech, founded in 2015 and based in West Palm Beach, Florida, is a biotechnology company dedicated to advancing cell and gene therapies for cancer and autoimmune diseases. The company is currently in the clinical stage, focusing on innovative solutions that improve patient access to cutting-edge treatments. Their proprietary platforms, including the rPOC SC and GCAR, are designed to optimize the efficacy and safety of CAR-T therapies, allowing for administration without the need for lymphodepleting chemotherapy. EXUMA's technologies aim to address the limitations of traditional cell therapies, making them more accessible and effective for patients. The company has received significant funding, with a Series B round raising $41 million in December 2021, which supports their ongoing research and development efforts in the cancer treatment space.

16. Inceptor Bio

• Website: inceptor.bio
• Ownership type: Corporate
• Headquarters: Morrisville, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $21.0M, February 2025
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: inceptor-bio

Inceptor Bio, founded in 2020 and based in Morrisville, North Carolina, is a biotechnology firm dedicated to advancing cell therapies for cancer treatment. The company specializes in innovative solutions such as the OUTLAST™ CAR T platform and CAR-M therapies, which aim to tackle the challenges posed by solid tumors. Inceptor Bio's primary customers include healthcare providers and research institutions seeking effective cancer therapies. Recently, the company secured $21 million in Series A funding, which underscores its potential for growth and development in the oncology space. With a focus on reprogramming T cells to maintain their effectiveness in the tumor microenvironment, Inceptor Bio is poised to make significant contributions to the field of cancer treatment.

17. Ensoma

• Website: ensoma.com
• Ownership type: Private Equity
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 97%, Denmark 3%
• Latest funding: Series B, $50.0M, May 2023
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: ensomabio

Ensoma is a biotechnology firm based in Boston, Massachusetts, founded in 2019. The company specializes in developing innovative medical treatments through its proprietary Engenious™ platform. This platform allows for the creation of one-time in vivo therapies that engineer immune cells, targeting diseases such as cancer and autoimmune disorders. Ensoma's approach is notable for its potential to provide curative solutions by precisely modifying immune cells. The company has recently secured significant funding, including a $50 million Series B round in May 2023, which underscores investor confidence in their mission to pioneer new therapeutic strategies. With a dedicated team and a clear focus on advancing cancer treatment, Ensoma is positioned to make meaningful contributions to the field of gene therapy.

18. Obsidian Therapeutics

• Website: obsidiantx.com
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $160.5M, April 2024
• Founded year: 2015
• Headcount: 51-200
• LinkedIn: obsidian-therapeutics

Obsidian Therapeutics, founded in 2015 and based in Cambridge, Massachusetts, is a biotechnology company that specializes in engineered therapeutics with a focus on cell and gene therapy. The company utilizes its proprietary cytoDRiVE® platform to create precision medicines aimed at treating advanced melanoma, which is reflected in their lead clinical program, OBX-115. Obsidian has garnered significant financial backing, with a recent Series C funding round raising $160.5 million in April 2024. This funding supports their ongoing research and development efforts. The company has also received notable FDA designations, including the Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for OBX-115, underscoring their innovative approach to cancer treatment. Their work is directed towards providing patients and healthcare providers with advanced therapeutic options, positioning them as a relevant player in the cancer gene therapy field.

19. TCRCure Biopharma Corp.

• Website: en.tcrcure.com
• Ownership type: Private
• Headquarters: Guangzhou, Guangdong, China
• Employee distribution: United States (USA) 67%, China 33%
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: tcrcure-biopharma-corp

TCRCure Biopharma Corp., founded in 2016 and based in Guangzhou, China, is a biopharmaceutical company dedicated to advancing cancer immunotherapy. The firm specializes in developing innovative T cell therapies, particularly focusing on TCR-T cell therapies aimed at treating various cancers, including cervical cancer and other solid tumors. TCRCure operates research and development centers and manufacturing facilities in both the United States and China, ensuring compliance with current Good Manufacturing Practices (cGMP). The company has made significant strides in clinical trials, notably receiving IND approval for its TC-E202 therapy, which targets HPV-positive cervical cancer. With a team comprising many Ph.D. holders and a commitment to bridging research with clinical application, TCRCure is actively contributing to the evolution of cancer treatment options.

20. FinVector Oy

• Website: finvector.com
• Ownership type: Private
• Headquarters: Kuopio, North Savo, Finland
• Employee distribution: Finland 99%
• Latest funding: Other (Debt), $48.2M, June 2023
• Founded year: 1993
• Headcount: 201-500
• LinkedIn: finvector-vision-therapies-oy

FinVector Oy, based in Kuopio, Finland, is a biopharmaceutical company that specializes in the manufacturing of viral-based gene therapy products. Founded in 1993, the company has established itself as a key player in the biopharmaceutical sector, particularly in the area of cancer treatment. FinVector focuses on improving the lives of patients with chronic health conditions, with a notable emphasis on bladder cancer. They operate a state-of-the-art manufacturing facility that adheres to current Good Manufacturing Practices (cGMP), ensuring the highest standards of safety and efficacy in their products. Recently, FinVector has gained attention for its collaboration with Ferring Pharmaceuticals, producing the FDA-approved gene therapy Adstiladrin for non-muscle invasive bladder cancer. The company has also secured significant funding, with a recent amount of approximately €48 million reported in June 2023, which supports their ongoing innovation and expansion efforts in the gene therapy space.

21. Biosceptre International Limited

• Website: biosceptre.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, England, United Kingdom (UK)
• Latest funding: Series A, January 2023
• Founded year: 2000
• Headcount: 11-50
• LinkedIn: biosceptre-international

Biosceptre International Limited, based in Cambridge, UK, is a biopharmaceutical company dedicated to developing innovative cancer therapies. Founded in 2000, the company specializes in the BRiDGECAR™ system, which integrates nfP2X7-targeted technology with CAR T-cell therapy and multiple targeted antibodies. This unique approach aims to improve treatment outcomes for various malignancies. Biosceptre's research is supported by collaborations with esteemed institutions, including the University of Sydney. The company is currently advancing its CAR T program, which has the potential to treat a wide range of hematological and solid tumors. Their commitment to research and development is evident in their ongoing clinical trials and recent funding efforts to enhance their therapeutic programs.

22. Triumvira Immunologics, Inc.

• Website: triumvira.com
• Ownership type: Venture Capital
• Headquarters: Austin, Texas, United States (USA)
• Employee distribution: United States (USA) 65%, Canada 35%
• Latest funding: Series A, $45.0M, March 2022
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: triumvira-immunologics-inc

Triumvira Immunologics, Inc., founded in 2015 and based in Austin, Texas, is a biotechnology firm dedicated to developing innovative T cell therapies for cancer. The company specializes in its proprietary T cell Antigen Coupler (TAC) technology, which enhances the immune system's ability to recognize and attack tumors. Triumvira's approach is particularly focused on both autologous and allogeneic T cell therapies, aiming to provide effective treatment options for patients with difficult-to-treat cancers. Their lead candidate, TAC101-CLDN18.2, targets claudin 18.2-positive solid tumors and is currently in clinical trials. The company has received significant venture capital funding, with a notable $45 million raised in March 2022, which supports their ongoing research and development initiatives. Triumvira's commitment to advancing T cell therapy positions it as a relevant player in the cancer treatment landscape.

23. EdiGene Inc.

• Website: edigene.com
• Ownership type: Private Equity
• Headquarters: Beijing, Beijing, China
• Employee distribution: China 100%
• Latest funding: Series B, $61.6M, April 2021
• Founded year: 2015
• Headcount: 201-500
• LinkedIn: edigene

EdiGene Inc., founded in 2015 and based in Beijing, China, is a biotechnology firm dedicated to pioneering gene editing and therapy solutions. The company aims to address significant unmet medical needs, particularly in cancer and genetic disorders, through its advanced platforms for RNA editing and cell therapy. EdiGene's product pipeline includes innovative therapies such as CAR-T treatments targeting difficult-to-treat cancers like non-Hodgkin lymphoma. The company has received substantial funding, with a Series B round totaling approximately $61.6 million in April 2021, which supports its research and development efforts. EdiGene's commitment to transforming treatment options for patients is evident in its active participation in clinical trials and collaborations with leading medical institutions.

24. Curocell

• Website: curocellbtx.com
• Ownership type: Private Equity
• Headquarters: Daejeon, Daejeon, South Korea
• Employee distribution: South Korea 100%
• Latest funding: $30.1M, January 2022
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: curocell

Curocell, founded in 2016 and based in Daejeon, South Korea, is a biotechnology firm dedicated to advancing CAR-T cell therapy and related technologies. The company aims to provide innovative treatment options for cancer patients by collaborating with hospitals and medical institutions. Curocell's proprietary OVIS™ platform technology enhances the efficacy of CAR-T therapies by addressing immune suppression, a common challenge in cancer treatment. This technology allows for the simultaneous expression of CAR and downregulation of immune checkpoint receptors, improving the anti-tumor activity of CAR-T cells. Curocell has been actively involved in clinical contracts with various medical institutions, indicating their commitment to bringing their therapies to market. In January 2022, they secured funding of approximately $30 million, which underscores their growth potential and ongoing research initiatives.

25. East Ocyon Bio Private Limited

• Website: eastocyonbio.com
• Ownership type: Venture Capital
• Headquarters: Faridabad, Haryana, India
• Employee distribution: India 100%
• Latest funding: Seed, $4.2M, December 2024
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: east-ocyon-bio-private-limited

East Ocyon Bio Private Limited, founded in 2022 and based in Faridabad, Haryana, India, is a biotechnology firm dedicated to advancing cancer treatment through cell and gene therapy. The company specializes in harnessing the power of natural killer (NK) cells, a type of immune cell known for its ability to target and destroy tumor cells. Their innovative approach includes the development of allogeneic CAR-NK cell therapies and genome editing technologies, such as CRISPR/Cas9, aimed at enhancing the efficacy of cancer treatments. East Ocyon Bio operates with a mission to provide early, affordable, and quality access to curative therapies for patients in India and around the world. The company has attracted significant venture capital funding, with a recent seed round raising $4.2 million in December 2024, which underscores its potential in the competitive landscape of cancer gene therapy. Their collaborations with healthcare providers and participation in industry conferences further highlight their active involvement in the sector.

Cancer Gene Therapy Insights: Key Companies

Want to Find More Cancer Gene Therapy Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!